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Abstract. Estrogens and tamoxifen do not only exert their 
effects at the genomic level, but also play a role at the cell 
membrane activating downstream signaling pathways. We 
recently characterized an estrogen receptor-positive epithelial 
murine breast cancer cell line, LM05-E. Utilizing this cell 
line and MCF-7 cells, we compared the non-genomic effects 
of estradiol and 4-OH-tamoxifen. We showed that, similar to 
estradiol, tamoxifen activated the MAPK/ERK 1/2 pathway; 
however, we did not find activation of PI3K/AKT by either 
estradiol or tamoxifen. Short-term treatments with estradiol 
stimulated, whereas tamoxifen inhibited cell proliferation. 
Using pharmacological inhibitors we showed that the effect 
of estradiol was mediated by the MAPK/ERK 1/2 pathway, 
but that inhibition of this pathway did not affect tamoxifen. 
Surprisingly, however, blocking of PI3K/AKT signaling inter-
fered with the inhibitory effect of tamoxifen. Analysis of the 
involvement of the EGFR support previous findings that desig-
nate this receptor as a mediator of the non-genomic effects of 
estradiol; blocking EGFR also reverses the inhibitory effect 
of tamoxifen. Finally, matrix metalloproteinases (MMPs) 
were confirmed to be involved in the proliferative effect of 
estradiol. These results demonstrated the novel non-genomic 
effects of tamoxifen and revealed that pathways downstream 
of EGFR and PI3K/AKT are involved in the inhibition of cell 
proliferation. Caution should be exercised when analyzing 
strategies that aim at combining endocrine therapy with 
specific signaling inhibitors.
Introduction
Estrogen receptors play a key role in breast cancer progres-
sion (1). Seventy-five percent of women diagnosed with 
breast cancer have estrogen and progesterone receptor (ER, 
PR)-positive breast tumors (2,3). Tamoxifen, a selective ER 
modulator, is the main five-year adjuvant treatment for these 
patients (4). However, one third of patients treated with tamox-
ifen will suffer from a recurrence within 15 years (5). Thus, 
understanding the mechanisms involved in the development of 
endocrine resistance is of great clinical relevance.
ERs are steroid receptors that are located not only in the 
nucleus, but also in the cytoplasm, the mitochondria, the 
endoplasmic reticulum and the plasma membrane (6). Plasma 
membrane ERs were first identified in endometrial cells (7). 
In breast cancer cells, the main plasma membrane ER which 
constitute ~5-10% of the total ERs, is ER-α; little ER-β is 
found at this location (8). Apart from the ERs, several other 
membrane receptors have been proposed as mediators of 
the non-genomic actions of estrogens (6,9,10). Nonetheless, 
ER-α is believed to be the main receptor responsible for rapid 
signaling in response to estrogens in established experimental 
conditions in mammary cells (6). ER-α forms a ternary 
complex together with the IGF-R1 and the adaptor protein SHC 
in the presence of estradiol (10). Binding of estradiol to ER-α 
leads to activation of SHC and the formation of the complex 
followed by the phosphorylation of ER and the IGF-R1 by 
the c-Src kinase (10). Other authors have proposed a linear 
pathway implicating activation of the IGF-R1 followed by 
activation of matrix metalloproteinases (MMPs) which leads 
to the release of HB-EGF. EGF binds to its receptor leading 
to activation of the MAPK/ERK 1/2 and PI3K/AKT pathways 
downstream (11). Notably, few publications to the best of our 
knowledge, have investigated the effect of tamoxifen on plasma 
membrane ER and its subsequent non-genomic actions (12).
We developed a mouse model of estrogen-dependent 
breast cancer from a spontaneous tumor that arose in a 
female BALB/c mouse in our animal facility (13). This 
tumor, called M05, is positive for ER and PR and responds 
to tamoxifen within the first 9 passages (13). From this tumor 
we established the epithelial cell line LM05-E that is ER- and 
PR-positive and is responsive to estradiol and tamoxifen 
as determined by proliferation and apoptosis assays (14). In 
the present study we investigated the non-genomic effects of 
estradiol and tamoxifen on the LM05-E cell line. We addi-
tionally used MCF-7 cells as a control. We established that, 
similar to estradiol, tamoxifen activates the MAPK/ERK 1/2 
pathway in breast cancer cells; however, we did not find any 
effect of either estradiol or tamoxifen on the activation status 
of PI3K/AKT. Short-term treatments with estradiol stimu-
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lated, whereas tamoxifen inhibited, cell proliferation. Using 
pharmacological inhibitors we showed that, as previously 
described, the effect of estradiol is mediated by the MAPK/
ERK 1/2 pathway. Inhibition of this pathway did not affect the 
effect of tamoxifen. notably, however, blocking of PI3K/AKT 
signaling interfered with the inhibitory effect of tamoxifen by 
reversing it. Analysis of the involvement of the EGFR support 
previous findings that designate this receptor as a mediator of 
the non-genomic effects of estradiol. Unexpectedly, blocking 
EGFR also reversed the inhibitory effect of tamoxifen. Finally, 
MMPs were confirmed as being involved in the proliferative 
effect of estradiol but not on the inhibitory effect of tamoxifen. 
These results demonstrated the novel non-genomic effects of 
tamoxifen and revealed that pathways such as EGFR upstream 
of PI3K/AKT are involved in inhibition of cell proliferation. 
Consideration of these mechanisms should be taken into 
account when analyzing strategies that aim at combining 
endocrine therapy with specific signaling inhibitors.
Materials and methods
Cell culture. The MCF-7 and LM05-E cell lines were routinely 
maintained in growth medium, consisting of DMEM/F12 
medium (Sigma-Aldrich), supplemented with 10% fetal calf 
serum (FCS; GenSA, Buenos Aires, Argentina) and genta-
micin, in a humidified 5% Co2/air atmosphere. Serial passages 
were carried out by treatment of 80% confluent monolayers 
with 0.25% trypsin (Invitrogen) and 0.02% EDTA in Ca2+-free 
and Mg2+-free PBS.
Reagents. Estradiol and 4-OH-tamoxifen (both from Sigma-
Aldrich) were prepared 1000X in absolute ethanol and used 
at a final concentration of 10 nM and 1 µM, respectively. 
Controls were subjected to the same dilution of absolute 
ethanol. The MAPK/ERK 1/2 inhibitor PD98059 (10 µM), 
PI3K/AKT inhibitor lY294002 (10 µM), the matrix metallo-
proteinase inhibitor GM6001 (10 µM) and the EGFR inhibitor 
AG1478 (6.4 µM) were all purchased from Calbiochem, and 
Wortmannin (100 nM) was purchased from Sigma-Aldrich. 
They were prepared in DMSO, in at least 1000X stock solu-
tions, and the equivalent dilutions of DMSO were used as 
controls. We previously confirmed the effectiveness of these 
inhibitors on LM05-E and MCF-7 cells (15).
Cell proliferation studies. Cells (3.0x104/well) were plated in 
12-well plates in growth medium. The next day, cells were 
washed twice with PBS and the medium was replaced with 
phenol red-free DMEM/F12. After 48 h, cells were treated 
with either estradiol (10 nM) or 4-OH-tamoxifen (1 µM) (or 
vehicle) for up to 60 min and were then washed 5 times with 
PBS as previously published elsewhere (16). Subsequently, 
cells were cultured for an additional 48 h in phenol red-free 
DMEM/F12 supplemented with 1% charcoal stripped serum. 
Cells were then counted using a Neubauer chamber. To test the 
effects of the pharmacological inhibitors on the proliferative 
response to both estradiol and tamoxifen, starved cells were 
pretreated with the corresponding inhibitor (or vehicle) for 1 h, 
and were then subjected to either estradiol or 4-oH-tamoxifen 
exposure. All experiments were carried out in triplicates and 
repeated at least three times.
Western immunoblot assay. To evaluate the activation of the 
different signaling pathways by estradiol and 4-OH-tamoxifen, 
LM05-E cells (6.0x105) were plated on 60-mm plates in 
growth medium. The next day, cells were washed twice and 
the medium was replaced by phenol red-free medium. Cells 
were starved for 48 h and were then subjected to treatment 
with estradiol (10 nM) or 4-OH-tamoxifen (1 µM) for the 
indicated periods of time. To examine the effect of the specific 
inhibitors on the activation of the signaling pathways, starved 
cells were pretreated for 1 h with the inhibitors (or the corre-
sponding dilution of DMSO) and were subsequently treated 
with either estradiol or 4-OH-tamoxifen. Protein extracts were 
prepared by homogenizing cells on ice in RIPA buffer (50 mM 
Tris, pH 8.0 containing 150 mM NaCl, 0.1% SDS, 0.5% deoxy-
cholate and 1% NP-40) containing protease inhibitors (40 µm 
phenylmethylsulfonyl fluoride, 5 µg/ml leupeptin, 50 µg/ml 
aprotinin and 200 µM orthovanadate). Protein concentrations 
were measured using the Bradford method. Samples were 
mixed with 4X sample buffer containing β-mercaptoethanol 
and boiled for 2 min. Fifty micrograms of each sample was 
then separated on SDS-PAGE Mini gels (Bio-Rad) and trans-
ferred to PvDF membranes (Amersham Biosciences, Uppsala, 
Sweden). The membranes were blocked overnight in 5% fat-
free milk, 0.1% Tween-20 in PBS at 4˚C. Primary antibodies 
were used at a 1/500-1/2,000 dilution in PBS containing 0.1% 
Tween-20 (PBST) and 2.5% fat-free milk, and were incubated 
at 4˚C overnight. After washing with PBST, the membranes 
were incubated with secondary antibodies at a 1/1,000 
dilution for 1 h at room temperature. Signals were detected 
with an enhanced chemiluminescence kit (ECL; Amersham 
Biosciences). The following primary antibodies were used: 
mouse anti-phospho-ERK 1/2, mouse anti-ERK 1/2, rabbit 
anti-phospho-AKT and rabbit anti-AKT (all from Santa Cruz 
Biotechnology). The following secondary antibodies were 
used: donkey-anti rabbit HRP and goat anti-mouse HRP (Santa 
Cruz Biotechnology). To evaluate the effects of the inhibitors 
on the activation of the signaling pathways, the inhibitor and 
vehicle-treated samples were run on the same gel using 15 lane 
combs.
Statistical analysis. The statistical significance of differences 
between the groups was calculated by applying one-way 
AnovA, followed by Tukey's multiple comparisons test. 
A value of P<0.05 was considered to indicate a statistically 
significant result.
Results
Activation of signaling pathways by estradiol and 
4-OH-tamoxifen in LM05-E cells. To determine the non-
genomic responses of LM05-E cells to 17-β-estradiol and 
4-oH-tamoxifen, we first examined by western blot analysis 
the activation of the MAPK/ERK signaling pathway. As previ-
ously shown (14), short-term treatments with 10 nM estradiol 
led to a strong phosphorylation of ERK 1/2 by 10 min that 
declined to basal levels by 60 min (Fig. 1A). The same analysis 
on cells treated with 1 µM 4-OH-tamoxifen showed a weaker 
phosphorylation of ERK at 5-10 min with the signal declining 
by 60 min (Fig. 1B). Ethanol-treated cells, in contrast, did not 
show a significant activation of ERK 1/2 under these experi-
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mental conditions (Fig. 1C). To further establish whether 
the PI3K/AKT pathway is involved, western blots against 
phosphorylated AKT were carried out on cells receiving 
the identical treatments. Significant activation of AKT by 
estradiol or 4-OH-tamoxifen was not detected under our the 
experimental conditions (Fig. 2A). Moreover, we tested 10% 
FCS as a positive control and found that under these condi-
tions no significant AKT activation was observed (Fig. 2B). 
However, we observed that PI3K inhibitors were able to reduce 
AKT phosphorylation (Fig. 2C). Thus, our results suggest that 
estradiol and 4-OH-tamoxifen activate the MAPK/ERK 1/2 
pathway in LM05-E cells as previously reported by others in 
MCF-7 cells (12) and that there was a high basal activation of 
AKT in our model.
Proliferative response of LM05-E cells to short-term treat-
ments of estradiol and 4-OH-tamoxifen. To investigate the 
proliferative response of LM05-E cells to short-term treat-
ments of 17-β-estradiol and 4-OH-tamoxifen, we treated cells 
that had been starved in serum-free medium for 48 h with 
10 nM estradiol, 1 µM 4-OH-tamoxifen or vehicle for up to 
1 h. The wells were subsequently washed 5 times with PBS, 
and the medium was replaced by phenol red-free DMEM/F12 
supplemented with 1% charcoal stripped serum as described 
in Materials and methods and published by others (16). 
Forty-eight hours later, cells were counted to establish the 
effect of the treatments on cell proliferation. Treatment with 
estradiol induced an increase in the total number of cells, 
and 4-OH-tamoxifen, in contrast, inhibited cell prolifera-
tion when compared to the vehicle-treated control (Fig. 3A). 
Using the same experimental setting, similar results were 
obtained with MCF-7 cells (Fig. 3B). Given that treatment 
with 4-OH-tamoxifen reduced cell proliferation between 30 
and 50%, we investigated whether significant results could 
be obtained with shorter periods of treatment. The effect of 
4-oH-tamoxifen continued to be significant with treatments 
as brief as 15 min (Fig. 3C). To establish whether the effects 
of the short-term treatments with 4-OH-tamoxifen were being 
Figure 1. Treatment with estradiol or 4-OH-tamoxifen leads to the rapid phosphorylation of MAPK/ERK 1/2 in LM05-E cells. (A) Time course of ERK 
1/2 phosphorylation by estradiol. LM05-E cells plated in 60-mm plates were starved for 48 h and then treated with 10 nM estradiol for the indicated times. 
Proteins were extracted with RIPA buffer and analyzed by western blot analysis. A representative western blot analysis is shown on the left together with 
the densitometric analysis of three independent experiments on the right. A statistically significant activation of ERK was detected at 10 sec (10') (**P<0.01). 
(B) Cells starved as in A were treated for the indicated times with 1 µM 4-OH-tamoxifen, and the proteins were subsequently analyzed by western blot analysis. 
The densitometric analysis on the right corresponds to three independent experiments. As with estradiol, a statistically significant activation of ERK 1/2 
was detected (*P<0.05 and ***P<0.001). (C) Western blot analysis showing lack of activation of ERK 1/2 in the presence of ethanol. To verify that the effects 
observed for estradiol and tamoxifen were not due to the presence of the vehicle ethanol, or the manipulation of the cells, the protocol was carried out in the 
presence of ethanol on its own. As shown, no activation of ERK 1/2 was detected under these experimental conditions. Three independent experiments are 
represented in the graph. 
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mediated through the same receptor as estradiol, LM05-E 
cells were pre-treated for 15 min with 10 nM estradiol and 
subsequently 1 µM 4-OH-tamoxifen was added for 1 h. Forty-
eight hours later, the effect on cell proliferation showed that 
estradiol only partially counteracted the effects of tamoxifen 
(Fig. 3D), suggesting that the ER is involved in this mecha-
nism. However, it has also been proposed by other authors, 
that tamoxifen may exert its effects through ER-dependent and 
-independent mechanisms (17).
The MAPK/ERK pathway is involved in the proliferative 
response to estradiol whereas the PI3K/AKT pathway medi-
ates the inhibitory effect of 4-OH-tamoxifen. We established 
above that short-term treatments with estradiol stimulated 
while 4-OH-tamoxifen inhibited the proliferation of LM05-E 
cells; however, both effects were accompanied by an increase 
in ERK phosphorylation and no changes in AKT phosphoryla-
tion. To further establish the involvement of the downstream 
signaling pathways, we pre-treated LM05-E cells with the MEK 
inhibitor PD98059 (10 µM) or the PI3K inhibitors lY294002 
(10 µM) and Wortmannin (100 nM) and then subjected them 
to short pulses of estradiol and 4-OH-tamoxifen as explained 
above. Pre-treatment with PD98059 abrogated the stimulatory 
effects of estradiol on cell proliferation (Fig. 4A), but did not 
affect the inhibitory effect of 4-OH-tamoxifen (Fig. 4B). On 
the other hand, LY294002 did not affect the stimulatory effect 
of estradiol (Fig. 4C). However, inhibition of the PI3K/AKT 
pathway with either LY294002 or Wortmannin reversed 
the inhibitory effect of 4-OH-tamoxifen (Figs. 4D and 5A). 
Pretreatment with Wortmaninn or LY294002 also reversed the 
inhibitory effect of 4-OH-tamoxifen on MCF-7 cells (Fig. 5B 
and C); however, the MEK inhibitor, as in the case of LM05-E 
cells, did not have an impact on the effect of the anti-estrogen 
(Fig. 5D). Our results thus suggest that the MAPK/ERK 
pathway plays a key role in mediating the stimulatory effect 
of estradiol whereas the PI3K/AKT pathway is involved in the 
inhibitory effect of 4-OH-tamoxifen.
EGFR mediates the downstream effects of both estradiol and 
4-OH-tamoxifen, while MMPs are only involved in the effects 
of estradiol. It has been previously shown in MCF-7 cells that 
binding of estradiol to membrane ER leads to the shedding 
of HB-EGF by MMPs and the subsequent activation of the 
MAPK/ERK pathway (11). To investigate whether EGFR is 
involved in the proliferative response to short-term treatment 
with estradiol or 4-OH-tamoxifen in LM05-E cells, we pre-
incubated the cells with the EGFR inhibitor AG1478 (6.4 µM) 
and then incubated the cells with estradiol or 4-OH-tamoxifen 
for 1 h. The EGFR inhibitor completely blocked the increase 
in cell number induced by estradiol (Fig. 6A). Western blot 
analysis showed that inhibition of EGFR led to reduced acti-
vation of MAPK/ERK (Fig. 6B). Moreover, it abrogated the 
inhibitory effect of 4-OH-tamoxifen in both LM05-E (Fig. 6C) 
and MCF-7 cells (data not shown) as previously revealed (12). 
Western blot analysis showed that 4-OH-tamoxifen induced 
MAPK/ERK 1/2 activation was also inhibited (Fig. 6D) 
Figure 2. Estradiol and 4-OH-tamoxifen did not activate AKT in LM05-E cells. (A) Time course of AKT phosphorylation by estradiol and 4-OH-tamoxifen. 
LM05-E cells plated in 60-mm plates were starved for 48 h and then treated for the indicated times with 10 nM estradiol or 1 µM 4-OH-tamoxifen. Proteins 
were extracted with RIPA buffer and analyzed by western blot analysis. no change in the phosphorylation of AKT was detected by either treatment. one of 
at least three independent experiments is shown for each treatment. (B) Activation of AKT by tamoxifen or FCS pulses. LM05-E cells plated in 60-mm plates 
were starved for 48 h and then treated for 15 min with tamoxifen (Tam) (1.10-6 M) or 10% FCS. Proteins were extracted with RIPA buffer and analyzed by 
western blot analysis. A representative western blot analysis is shown with its corresponding densitometric analysis. (C) Inhibition of AKT by PI3K inhibitors. 
LM05-E cells plated in 60-mm plates were starved for 48 h and then treated for 1 h with medium with LY294002 (LY) (10 µM) or Wortmannin (W) (100 nM). 
Proteins were extracted with RIPA buffer and analyzed by western blot analysis. A representative western blot analysis with its densitometric analysis is shown.
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Figure 3. Short-term treatments with estradiol and 4-OH-tamoxifen modulate the proliferation of LM05-E cells. Cells starved for 48 h in 12-well plates were 
treated for up to 1 h with 10 nM estradiol or 1 µM 4-OH-tamoxifen in culture media in the absence of serum, washed, and counted 48 h later as described in 
Materials and methods. (A) A statistically significant increase in cell number was detected in the lM05-E cells treated with estradiol (E2). 4-OH-tamoxifen 
(Tam) had an inhibitory effect as expected. Controls were treated with the vehicle ethanol (ETOH) (**P<0.01; ***P<0.001). (B) The same experimental setting 
was used as in A on MCF-7 cells. Similar results were obtained with an increase in cell number in the presence of E2 and a reduction following treatment 
with 4-OH-tamoxifen (***P<0.001). (C) 4-oH-tamoxifen led to a statistically significant inhibition of cell proliferation with treatments as short as 15 min (15'). 
The same experimental setting was used as above, with reduced exposure time to 4-OH-tamoxifen (**P<0.01; ***P<0.001). (D) Treatment with estradiol (E2) 
partially counteracted the effect of 4-OH-tamoxifen (Tam). LM05-E cells were starved and pre-incubated with estradiol for 15 min before being exposed 
to 4-oH-tamoxifen for 1 h as explained above. A statistically significant partial reversal of the inhibitory effect of 4-oH-tamoxifen was achieved (*P<0.05; 
***P<0.001) suggesting that this SERM exerts its effects through ER-dependent and -independent mechanisms. One of three representative experiments is 
shown for all experiments. 
Figure 4. Role of the MAPK/ERK and PI3K/AKT pathways in the non-genomic effects of estradiol on lM05-E cells. (A) lM05-E cells starved for 48 h were 
pre-incubated with the MAPK/ERK inhibitor PD98059 (PD) (10 µM) or vehicle (DMSO) for 1 h before being exposed to short-term treatment with estradiol 
(E2). Cells were then washed and incubated as described in Materials and methods and counted 48 h later. PD inhibited the increase in cell number induced 
by estradiol in a statistically significant manner (***P<0.001). It had no effect on its own. (B) Starved lM05-E cells were pre-incubated with PD as explained 
above and subsequently treated with 4-oH-tamoxifen (Tam) for 1 h and counted 48 h later. PD had no influence on the inhibitory effect of tamoxifen (**P<0.01; 
***P<0.001). (C) lM05-E cells were starved and pre-treated with the PI3K/AKT inhibitor lY294002 (lY) (10 µM). lY did not a have statistically significant 
effect on the proliferation induced by estradiol (*P<0.05; **P<0.01). (D) However, pre-treatment with LY reversed the inhibitory effect of 4-OH-tamoxifen on 
LM05-E cells (**P<0.01; ***P<0.001). 
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Figure 6. Involvement of the EGFR pathway in the non-genomic effects of estradiol and 4-oH-tamoxifen. lM05-E cells were starved and pre-treated for 1 h 
with the EGFR inhibitor AG1478 (AG) (6.4 µM). Subsequently, they were either treated with estradiol (E2) or 4-OH-tamoxifen (Tam) and analyzed for cell 
proliferation 48 h later, or MAPK/ERK phosphorylation within 6 h of treatment. (A) AG had a statistically significant inhibitory effect on cell proliferation 
induced by estradiol (E2) (**P<0.01; ***P<0.001). (B) This effect was associated with strong inhibition of ERK 1/2 phosphorylation as shown by western blot 
analysis. As in A, the control cells were pre-treated with DMSO. (C) As in the case of estradiol, AG counteracted the effect of 4-OH-tamoxifen. A statistically 
significant reversal of the inhibitory effect of 4-oH-tamoxifen on cell proliferation was detected (**P<0.01; ***P<0.001). (D) Western blot analysis showed that 
phosphorylation of ERK induced by Tam was inhibited by AG, compared to the vehicle control treated with DMSO. One of three experiments is shown in 
each case.
Figure 5. Role of the MAPK/ERK and PI3K/AKT pathways in the non-genomic effects of 4-oH-tamoxifen and estradiol on lM05-E and MCF-7 cells. 
(A) lM05-E cells starved for 48 h were pre-incubated with the PI3K inhibitor Wortmannin (W) (100 nM) or vehicle (DMSo) for 1 h before being exposed 
to short-term treatments with 4-OH-tamoxifen (Tam). They were then washed and incubated as described in Materials and methods and counted 48 h later. 
Wortmannin reversed the inhibitory effect of 4-OH-tamoxifen (**P<0.01). It had no effect on its own. (B) Starved MCF-7 cells were pre-incubated with 
Wortmannin as explained above and subsequently treated with 4-OH-tamoxifen for 1 h and counted 48 h later. Wortmannin reversed the inhibitory effect of 
4-OH-tamoxifen (**P<0.01; ***P<0.001). It had no effect on its own. (C) MCF-7 cells were starved and pre-treated with the PI3K/AKT inhibitor lY294002 (lY) 
(10 µM); pre-treatment with LY reversed the inhibitory effect of 4-OH-tamoxifen on MCF-7 cells (*P<0.05; ***P<0.001). (D) Pre-treatment of MCF-7 cells with 
the MAPK/ERK inhibitor PD98059 (PD) (10 µM) did not disturb the inhibitory effect of 4-OH-tamoxifen (**P<0.01; ***P<0.001). One of three experiments is 
shown in each case. 
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suggesting that EGFR provides a point of convergence for both 
the stimulatory and inhibitory effects of these compounds, 
even though MAPK/ERK 1/2 appears to play a key role only 
in estradiol-induced cell proliferation.
To determine whether shedding of HB-EGF is also a 
common event leading to these distinct effects, LM05-E cells 
were pre-incubated with the MMP inhibitor GM6001 (10 µM) 
and then treated with either estradiol or 4-OH-tamoxifen. 
GM6001, as did AG1478, led to a reversal of the stimulatory 
effect of estradiol, but did not affect the inhibitory effect of 
4-OH-tamoxifen (Fig. 7A). Moreover, as noted in the western 
blot analysis, the MMP inhibitor consistently delayed the 
phosphorylation of ERK in the cells treated with estradiol 
(Fig. 7B); notably, this was also the case for the cells treated 
with 4-OH-tamoxifen (Fig. 7C). Thus, our results showed 
that similar to MCF-7 cells, the non-genomic effects of estra-
diol involve MMP activity and the participation of EGFR. 
Moreover, our results suggest that 4-OH-tamoxifen also 
requires an active EGFR to exert its biological effects even 
though MMP activity does not appear to play a role.
Discussion
In the present study, we investigated the non-genomic 
responses of murine LM05-E breast cancer cells to estra-
diol and 4-OH-tamoxifen. Through proliferation assays, 
based on a previously published method established by 
vallejo et al (16) and western blot analysis, we determined 
that, as previously shown for MCF-7 and T47D cells, short-
term exposure to estradiol and 4-OH-tamoxifen led to the 
phosphorylation of MAPK/ERK 1/2. As expected, treat-
ment with estradiol had a positive impact on cell number 
at 48 h, whereas 4-OH-tamoxifen had an inhibitory effect. 
Estradiol partially counteracted the inhibitory effect of 
4-OH-tamoxifen  suggesting that the ER is at least partially 
involved in tamoxifen membrane-initiated signaling. Analysis 
Figure 7. MMPs are mediators of the non-genomic effects of estradiol but not of 4-OH-tamoxifen. LM05-E cells were starved for 48 h and pre-treated for 1 h 
with the MMP inhibitor GM6001 (10 µM). Subsequently, they were either treated with estradiol (E2) or 4-OH-tamoxifen (Tam) and analyzed for cell prolifera-
tion 48 h later or for MAPK/ERK phosphorylation within 6 h of treatment. (A) GM6001 showed a statistically significant inhibitory effect on cell proliferation 
induced by the non-genomic effects triggered by estradiol (**P<0.01;***P<0.001), but did not affect the inhibitory effect of 4-OH-tamoxifen (right). (B) Western 
blot analysis revealed a delay in ERK 1/2 phosphorylation upon pre-incubation with GM6001 and subsequent estradiol treatment. The control was treated with 
the vehicle DMSO. The graph on the right represents the results of three independent experiments (*P<0.05). (C) Pre-treatment with GM6001 also delayed the 
activation of MAPK/ERK by 4-OH tamoxifen even though it did not affect the inhibition of proliferation (*P<0.05). The mean of three experiments is shown 
in the graph on the right.
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of the active involvement of the signaling pathways on the 
non-genomic responses using specific inhibitors revealed 
that MAPK/ERK 1/2 mediates the proliferative response to 
estradiol, but not the inhibitory effect of 4-OH-tamoxifen. On 
the other hand, we did not find an involvement of PI3K/AKT 
in the response to estradiol; surprisingly, however, LY294002 
reversed the inhibitory effect of 4-OH-tamoxifen, suggesting 
that PI3K/AKT mediates the inhibitory effect of tamoxifen. 
Moreover, the PI3K inhibitor Wortmannin also abolished 
the inhibitory effect of tamoxifen, indicating that it is most 
probably due to PI3K inhibition and not other off-targets of 
LY294002, such as CK2 or GSK3β (18). Blocking EGFR 
strongly inhibited the activation of MAPK/ERK 1/2 induced 
by both estradiol and 4-OH-tamoxifen. With regards to prolif-
eration, EGFR mediated the stimulatory effect of estradiol, as 
previously shown by others, and, as in the case of the PI3K/
AKT pathway, its constraint neutralized the inhibitory effect 
of 4-OH-tamoxifen. Finally, we found that the MMP inhibitor 
GM6001 delayed the activation of ERK 1/2 by estradiol and 
4-OH-tamoxifen but had an impact only on the proliferative 
effect of estradiol.
Previously, several studies demonstrated that short-term 
treatment with estradiol led to the activation of the MAPK/ERK 
1/2 pathway in human breast cancer cells and other cell types 
such as endothelial cells (11,19). Few authors have investigated 
the non-genomic effects of 4-OH-tamoxifen and reported 
rapid activation of MAPK/ERK 1/2 by this SERM (12). 
Using LM05-E cells, we found that similar results were 
obtained regarding the MAPK/ERK 1/2 pathway, with rapid 
MMP-dependent phosphorylation following both estradiol and 
4-OH-tamoxifen treatments. We did not detect, however, any 
changes in AKT phosphorylation for either treatment or FCS 
pulses. This may be due to a high basal activation of AKT in 
our model. Nevertheless, activation of AKT by estradiol has 
been described for MCF-7 cells by Razandi et al (11). Together 
with the activation of the signaling pathways, we investigated 
the impact of each of these on cell proliferation as a measure 
of the long-term impact on cell behavior. As expected, 48 h 
after exposure to estradiol, a statistically significant increase 
in cell number was detected; conversely a decrease was found 
in culture plates treated with 4-OH-tamoxifen. Blocking the 
MAPK/ERK 1/2 pathway had a direct impact on the increase 
in cell number induced by estradiol, however, it did not affect 
the inhibitory effect of 4-OH-tamoxifen. This is contrary to 
the findings reported by Zheng et al (12) who described a 
reduction in cell death induced by 4-OH-tamoxifen in cells 
pre-treated with PD98059. However, the concentrations of both 
4-OH-tamoxifen and the MAPK/ERK inhibitors used by the 
other authors were higher than those used in the present study 
(5 and 20 µM, respectively), and the number of dead cells were 
counted up to 60 min after the initiation of the treatments as 
their end point. In contrast, we evaluated the effect of the treat-
ments on cell number 48 h later. Most interesting, however, 
was the finding that blocking PI3K/AKT counteracted the 
effect of 4-OH-tamoxifen. As mentioned above, we did not 
find a statistically significant change in AKT phosphorylation 
following treatment with either estradiol or 4-OH-tamoxifen 
on LM05-E cells, and LY294002 did not affect the increase 
in cell number induced by estradiol. In addition, we found that 
both LY294002 and Wortmannin reduced basal AKT activity. 
Other studies found increased phosphorylation of AKT as a 
result of non-genomic effects of estradiol (11,19). Notably, 
PI3K/AKT inhibition has been shown to promote resistance to 
chemotherapeutic drugs in MDA-MB-231 breast cancer cells 
as well as in other cell types such as DU-145 prostate, HCT-116 
colon and A-549 lung carcinoma cells (20). The authors found 
that this effect was only present when the cells were pre-incu-
bated with the PI3K/AKT inhibitor. on the contrary, when the 
timing was changed, with cells being exposed to LY294002 
after treatment with chemotherapeutic drugs, cell survival 
was decreased. Based on the same line of evidence, we found 
that inhibition of EGFR also reversed the inhibitory effect of 
4-OH-tamoxifen but additionally had an impact on the prolif-
erative effect of estradiol. Western blot analysis showed that 
AG1478 completely blocked the MAPK/ERK 1/2 pathway and 
this could account for the interference of the proliferative effect 
of estradiol. However, we did not find any change in the status 
of the PI3K/AKT pathway (data not shown) in the presence of 
AG1478 suggesting that some other pathway downstream of 
EGFR was accountable for the observed effect. Other authors 
have recently shown that inhibition of EGFR by various 
inhibitors increases ErbB3 protein levels in breast cancer 
cells and downregulates FAS which is involved in apoptotic 
cell death (21). On the other hand, HER2/HER3 heterodimer 
formation has been shown to be involved in EGFR inhibitor 
resistance in lung cancer cells (22).
Analysis of the effect of the MMP inhibitor GM6001 on cells 
treated with estradiol and 4-OH-tamoxifen showed that only 
in the case of estradiol did GM6001 have an effect. However, 
western blot analysis revealed that the MMP inhibitor delayed the 
phosphorylation of MAPK/ERK 1/2 induced by both estradiol 
and 4-OH-tamoxifen. The fact that at the proliferative level only 
cells treated with estradiol were affected supports our previous 
conclusion of the involvement of the MAPK/ERK 1/2 pathway 
as a mediator of the effect of estradiol, but not of tamoxifen.
Our results demonstrated that the selective estrogen 
receptor modulator 4-OH-tamoxifen stimulates non-genomic 
signaling in murine breast cancer cells. Even though the 
MAPK/ERK 1/2 pathway is activated as with estradiol, it 
does not appear to be a mediator of the effect of tamoxifen. 
Moreover, the PI3K/AKT pathway does not appear to be 
altered by tamoxifen treatment; however, its inhibition reverses 
the inhibitory effect of tamoxifen as does the blockage of the 
EGFR. These results suggest that caution should be exercised 
when considering the possibility of combining anti-estrogens 
with signaling pathway inhibitors as the latter may interfere 
with the non-genomic effects of tamoxifen and counteract part 
of its inhibitory effect.
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